Mesoblast MESO
NASDAQ MESO
$13.99 -0.45 (-3.12%)
At close: Nov 10, 2026 · 4:00 PM EST

Mesoblast (MESO) Current Deferred Revenue (2015 - 2016)

Updated

Mesoblast (MESO) recorded Current Deferred Revenue of $15 million in the quarter ended Mar 31, 2016, unchanged from the prior quarter.

Analysis

Mesoblast (MESO) Current Deferred Revenue (2015 - 2016) Analysis & Trends

Starting with the quarter ended Jun 30, 2015, Mesoblast's Current Deferred Revenue history includes 4 quarters.

  • Per Business Quant, the preceding three quarters came in at $15 million (quarter ended Dec 31, 2015), $15 million (quarter ended Sep 30, 2015) and $15 million (quarter ended Jun 30, 2015).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn
10 Mesoblast 1.84 Bn 1.40 Bn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2016 15.00 Mn
Dec 31, 2015 15.00 Mn
Sep 30, 2015 15.00 Mn
Jun 30, 2015 15.00 Mn
API Access

Mesoblast Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=MESO&period=max&api_key=YOUR_API_KEY